Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effects on erythropoietin and hematopoiesis in adults with type 2 diabetes and coronary artery disease
IRCT20190806044451N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoints: Serum erythropoietin level, Serum hematocrit level and 1 more. Started Aug 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20190806044451N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190806044451N1.